What is the translation of " B- CELLE " in English?

• b cell
• b-cell

Examples of using B- celle in Danish and their translations into English

Diffust storcellet B- celle non- Hodgkin lymfom.
Diffuse large B cell non-Hodgkin' s lymphoma.

Patienters HIV- status, HTLV- 1 for T- celle lymfomer og EVB status for B- celle lymfomer.
Patients HIV status, HTLV-1 for T-cell lymphomas and EVB status for B-cell lymphomas.

Det perifere B- celle tal faldt til under normalområdet efter den første dosis af MabThera.
Peripheral B cell counts declined below normal following completion of the first dose of MabThera.

Antigenet udtrykkes på> 95% af alle B- celle non- Hodgkin lymfomer.
The antigen is expressed on> 95% of all B cell non-Hodgkin' s lymphomas.

Diffust storcellet B- celle non- Hodgkin lymfom MabThera bør anvendes i kombination med CHOP kemoterapi.
Diffuse large B cell non-Hodgkin's lymphoma MabThera should be used in combination with CHOP chemotherapy.

Sikkerhedsdatabasen indeholder data fra patienter med multipelt myelom eller B- celle lymfocytisk leukæmi CLL.
The safety database comprises data from patients with multiple myeloma or B-cell lymphocytic leukemia CLL.

B- celle niveauer i spædbørn efter moderen havde været eksponeret for MabThera, er ikke undersøgt i kliniske forsøg.
B cell levels in human neonates following maternal exposure to MabThera have not been studied in clinical trials.

Det radiomærkede lægemiddel anvendes til behandling af voksne patienter med follikulær B- celle non- Hodgkins lymfom.
The radiolabelled medicine is used to treat adult patients with follicular B-cell non-Hodgkin' s lymphoma.

B- celle niveauet normaliseredes hos disse dyr indenfor 6 måneder efter fødslen og påvirkede ikke vaccinationsreaktionen.
B cell counts returned to normal in these animals within 6 months of birth and did not compromise the reaction to immunization.

Ibritumomab tiuxetan er et rekombinant murint IgG1 kappa- monoklonalt antistof specifikt for B- celle antigenet CD20.
Ibritumomab tiuxetan is a recombinant murine IgG1 kappa monoclonal antibody specific for the B-cell antigen CD20.

Farmakokinetikken blev beskrevet hos MabCampath- naive patienter med B- celle kronisk lymfatisk leukæmi(B- CLL), hvor tidligere behandling med purinanaloger havde slået fejl.
Pharmacokinetics were characterised in MabCampath-naive patients with B-cell chronic lymphocytic leukaemia(B-CLL) who had failed previous therapy with purine analogues.

Derfor kan vaccination med levende, virale vacciner ikke anbefales samtidig med MabThera behandling, eller mens der er perifer B- celle depletion.
Therefore vaccination with live virus vaccines is not recommended whilst on MabThera or whilst peripherally B cell depleted.

Hos patienter med reumatoid arthritis sås øjeblikkelig B- celle depletering i perifert blod efter to infusioner af 1000 mg MabThera med 14 dages interval.
In rheumatoid arthritis patients, immediate depletion of B cells in the peripheral blood was observed following two infusions of 1000 mg MabThera separated by a 14 day interval.

Nyfødte unger af dyremødre, der havde været eksponeret for MabThera, sås at have B- celle depletion i den postnatale fase.
New born offspring of maternal animals exposed to MabThera were noted to have depleted B cell populations during the post natal phase.

Under B- celle modning viser CD20 sig først i mellemstadiet af B- lymfoblast(præ- B- celle) og forsvinder under slutstadiet af B- cellernes modning til plasmaceller.
During B-cell maturation, CD20 is first expressed in the midstage of B-lymphoblast(pre-B-cell), and is lost during the final stage of B-cell maturation to plasma cells.

Studiet blev udført med deltagelse af 143 patienter med recidiverende eller refraktær non- Hodgkin' s lymfom(NHL) eller transformeret B- celle NHL.
The trial was conducted in 143 patients with relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma(NHL), or transformed B-cell NHL.

Hos patienter behandlet for hæmatologiske maligne sygdomme begyndte B- celle regenerering inden for 6 måneders behandling og nåede normale niveauer mellem 9 og 12 måneder efter afsluttet behandling.
In patients treated for hematological malignancies, B cell repletion began within 6 months of treatment returning to normal levels between 9 and 12 months after completion of therapy.

Rituximabs Fab domæne bindes til CD20 antigenet på B lymfocytter og Fc domainet kan rekruttere immuneffektor funktioner til at mediere B- celle lysis.
The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes and the Fc domain can recruit immune effector functions to mediate B cell lysis.

Udvalget konkluderede derfor at fordelene ved MabCampath opvejer risiciene til behandling af patienter med B- celle CLL, hos hvem kemoterapi kombineret med fludarabin ikke er hensigtsmæssig.
Therefore, the Committee concluded that MabCampath' s benefits are greater than its risks for the treatment of patients with B-cell CLL for whom fludarabine combination chemotherapy is not appropriate.

Dog blev der observeret dosisafhængigt farmakologisk B- celle depletion i fostrets lymfatiske organer, hvilket fortsatte efter fødslen og blev fulgt af et fald i IgG nivaeuet hos de påvirkede nyfødte dyr.
However, dose-dependent pharmacologic depletion of B cells in the lymphoid organs of the foetuses was observed, which persisted post natally and was accompanied by a decrease in IgG level in the newborn animals affected.

Studie 3 var et enkelt- arm studie med 30 patienter med recidiverende eller refraktær lavgrads, follikulær eller transformeret B- celle NHL, som havde mild trombocytopeni blodpladetal 100. 000 til 149. 000 eller/ mm3.
Study 3 was a single arm study of 30 patients with relapsed or refractory low-grade, follicular, or transformed B-cell NHL who had mild thrombocytopenia platelet count 100,000 to 149,000 cells/ mm3.

MabThera er, i kombination med CHOP- kemoterapi(cyclophosphamid, doxorubicin, vincristin og prednisolon), indiceret til behandling af patienter med CD20 positivt, diffust storcellet B- celle non- Hodgkin lymfom.
MabThera is indicated for the treatment of patients with CD20 positive diffuse large B cell non- Hodgkin' s lymphoma in combination with CHOP(cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.

Der foreligger ingen adækvate og velkontrollerede data fra studier hos gravide kvinder, men der er dog beskrevet forbigående B- celle depletion og lymfocytopeni hos børn af mødre, som har været eksponeret for rituximab under graviditeten.
There are no adequate and well-controlled data from studies in pregnant women, however transient B-cell depletion and lymphocytopenia have been reported in some infants born to mothers exposed to rituximab during pregnancy.

Udvalget for Humanmedicinske Lægemidler(CHMP) konkluderede, at fordelene ved Zevalin opvejer risiciene ved anvendelse som konsoliderende behandling efter remissionsinduktion hos ubehandlede patienter med follikulær lymfom og ved behandling af voksne patienter med CD20- positiv follikulær B- celle non- Hodgkins lymfom, som fik tilbagefald eller ikke responderede på behandlingen med rituximab.
The Committee for Medicinal Products for Human Use(CHMP) decided that Zevalin' s benefits are greater than its risks as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma and for the treatment of adult patients with rituximab relapsed or refractory CD20-positive follicular B-cell non-Hodgkin's lymphoma.

I denne undersøgelse var de fleste psoriasis artrit patienter behandlet med Enbrel i stand til at rejse en effektivt B- celle immunrespons mod pneumokok polysakkarid vaccine, men aggregattitrene var moderat lavere, og få patienter havde dobbelt stigning i titrene i sammenligning med patienter, som ikke fik Enbrel.
In this study most psoriatic arthritis patients receiving Enbrel were able to mount effective B-cell immune response to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and few patients had two-fold rises in titers compared to patients not receiving Enbrel.

Induktionsbehandling, 1 dosis ugentligt til ialt 8 doser I et enkelt- arms multicenterstudie fik 37 patienter med recidiveret elle kemoterapi- resistent lavmalignt eller follikulært B- celle NHL 375 mg/ m2 MabThera som intravenøs infusion ugentligt i otte doser.
Initial treatment, weekly for 8 doses In a multi-centre, single-arm study, 37 patients with relapsed or chemoresistant, low grade or follicular B cell NHL received 375 mg/ m2 of MabThera as intravenous infusion weekly for eight doses.

I et åbent, randomiseret studie fik 399 tidligere ubehandlede, ældre patienter(60- 80 år) med diffust storcellet B- celle lymfom standard- CHOP kemoterapi(cyklophosphamid 750 mg/ m2, doxorubicin 50 mg/ m2, vinkristin 1, 4 mg/ m2 op til maksimalt 2 mg på dag 1 og prednison 40 mg/ m2 på dag 1- 5) hver 3. uge i otte serier eller MabThera 375 mg/ m2 plus CHOP R- CHOP.
In a randomised, open-label trial, a total of 399 previously untreated elderly patients(age 60 to 80 years) with diffuse large B cell lymphoma received standard CHOP chemotherapy(cyclophosphamide 750 mg/ m2, doxorubicin 50 mg/ m2, vincristine 1.4 mg/ m2 up to a maximum of 2 mg on day 1, and prednisolone 40 mg/ m2/ day on days 1-5) every 3 weeks for eight cycles, or MabThera 375 mg/ m2 plus CHOP R-CHOP.

Monoterapi Induktionsbehandling, 1 dosis ugentligt til ialt 4 doser I det pivotale studie fik 166 patienter med recidiverende eller kemoterapi- resistent lavmalignt eller follikulært B- celle NHL 375 mg/ m2 MabThera som intravenøs infusion én gang om ugen i fire uger.
Monotherapy Initial treatment, weekly for 4 doses In the pivotal study, 166 patients with relapsed or chemoresistant low-grade or follicular B cell NHL received 375 mg/ m2 of MabThera as an intravenous infusion once weekly for four weeks.

Genbehandling, 1 dosis ugentligt til ialt 4 doser I et enkelt- arms multicenterstudie blev 58 patienter med recidiveret elle kemoterapi- resistent lavmalignt eller follikulært B- celle NHL, som havde opnået et objektivt klinisk respons efter en tidligere serie med MabThera, genbehandlet med 375 mg/ m2 MabThera som intravenøs infusion ugentligt i fire doser.
Re-treatment, weekly for 4 doses In a multi-centre, single-arm study, 58 patients with relapsed or chemoresistant low grade or follicular B cell NHL, who had achieved an objective clinical response to a prior course of MabThera, were re- treated with 375 mg/ m2 of MabThera as intravenous infusion weekly for four doses.